Q-linea AB (CHIX:QLINES) Marketable Securities: kr0.00 Mil (As of Mar. 2026)


CHIX:QLINES Q-linea AB CHIX:QLINES
67 GF Score
Price kr1,610.00
GF Value kr1,921.76
! 3 Warning Signs
View Full Analysis

What is Q-linea AB Marketable Securities?

Q-linea AB CHIX:QLINES 67 Marketable Securities is kr0.00 Mil as of Mar. 2026. GuruFocus rates CHIX:QLINES with a GF Score™ of 67/100 and a GF Value™ of kr1,921.76. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Q-linea AB's Marketable Securities for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Q-linea AB  (CHIX:QLINEs) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Q-linea AB Marketable Securities Related Terms

Q-linea AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for Q-linea AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-linea AB Marketable Securities Chart

Q-linea AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 150.72 0.00 0.00 0.00 0.00

Q-linea AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:QLINES
67GF Score
Q-linea AB CHIX:QLINES
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-linea AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr0.00 Mil mean?
Q-linea AB (CHIX:QLINES) has a Marketable Securities of kr0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Q-linea AB and its competitors.
Is Q-linea AB's Marketable Securities too high?
Q-linea AB's current Marketable Securities is kr0.00 Mil. Overall, Q-linea AB has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Marketable Securities compare to ABT and SYK?
Q-linea AB's Marketable Securities of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Q-linea AB and its competitors. Q-linea AB's current Marketable Securities is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Marketable Securities of kr0.00 Mil. The stock's GF Value™ is kr1,921.76, compared to a current price of kr1,610.00 — trading 16.2% below its estimated fair value. The current Marketable Securities is kr0.00 Mil. Q-linea AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Marketable Securities is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?

Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued. The current stock price of kr1,610.00 is trading 16.2% below its estimated GF Value™ of kr1,921.76.

Key valuation signals for CHIX:QLINES:

  • Marketable Securities: kr0.00 Mil
  • GF Value™: kr1,921.76 vs. price of kr1,610.00 (16.2% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Q-linea AB Business Description

Other Exchanges QLINEA:Sweden3F80:Germany
Address Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
67GF Score

Get the complete analysis for CHIX:QLINES

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,610.00
Price
kr1,921.76
GF Value